PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
03-Nov-2022 Aura Biosciences to Participate in Upcoming Investor Conferences Businesswire
03-Nov-2022 Teva Reports Third Quarter 2022 Financial Results Businesswire
03-Nov-2022 Gurnet Point Capital Appoints Stacey Seltzer as Partner Businesswire
03-Nov-2022 Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Businesswire
03-Nov-2022 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results Businesswire
03-Nov-2022 Radiopharmaceuticals Global Market to Reach $7.3 Billion by 2026 at a CAGR of 5.5% - ResearchAndMarkets.com Businesswire
03-Nov-2022 AmerisourceBergen Reports Fiscal 2022 Fourth Quarter and Year End Results Businesswire
03-Nov-2022 Global Smoking Cessation & Nicotine De-Addiction Product Market to Reach $40.6 Billion by 2027 at a CAGR of 9.39% - ResearchAndMarkets.com Businesswire
03-Nov-2022 Latest Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) (November 7-8, 2022) - ResearchAndMarkets.com Businesswire
03-Nov-2022 Cardior Appoints Axel-Sven Malkomes as Chief Financial Officer Businesswire
03-Nov-2022 Biodesix Announces Third Quarter 2022 Results and Highlights Businesswire
03-Nov-2022 Global Protected Feed Amino Acids Market Research Report to 2027 - Featuring Koninklijke DSM, Kyowa Kirin, Novus International and Otsuka Pharmaceutical Among Others - ResearchAndMarkets.com Businesswire
03-Nov-2022 The Worldwide Hunter Syndrome Treatment Industry is Expected to Reach $1.4 Billion by 2027 - ResearchAndMarkets.com Businesswire
03-Nov-2022 Sia Partners Accelerates in the Life Sciences Sector with the Acquisition of Latham BioPharm Group Businesswire
03-Nov-2022 Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome Businesswire
03-Nov-2022 Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Businesswire
03-Nov-2022 Aptar Again Named a Global Top Female-Friendly Company by Forbes Businesswire
02-Nov-2022 ICON Reports Third Quarter 2022 Results Businesswire
02-Nov-2022 IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma Businesswire
02-Nov-2022 Tricida Provides Strategic Update Businesswire